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ABSTRACT OF THE THESIS 
 
Neural Stem Cell-Derived Factors  
Mediate Neurovascular Regeneration  
in Ischemic Stroke 
 
by 
 
Handi Zhao 
 
Master of Science in Physiological Science 
University of California, Los Angeles, 2019 
Professor Rachelle Hope Watson, Co-Chair 
Professor Stanley Thomas Carmichael, Co-Chair 
 
Stroke is a leading cause of adult disability without treatment for long-term recovery. 
Stroke itself induces a wide-range of repair mechanisms, including the proliferation and long-
distance migration of immature neurons (neuroblasts) from the subventricular zone (SVZ) to peri-
infarct tissue. These neuroblasts localize to angiogenic blood vessels, forming a neurovascular 
niche in the peri-infarct zone. The reciprocal signaling between neuroblasts and endothelial cells 
has not been clearly characterized. A genome-wide expression profiling of stroke-induced 
neuroblasts and angiogenic vessels in the neurovascular niche led to the discovery of three 
differentially-regulated ligands derived from neuroblasts. These ligands are Wingless 7a (Wnt7a), 
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pleiotrophin (PTN), and chemokine (C-C motif) ligand 9 (CCL9). Mechanistic gain- and loss-of 
function studies show Wnt7a, PTN, and CCL9 mediate neural and vascular repair in the subacute 
and chronic periods after an ischemic cortical stroke.  
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 1 
Introduction 
 
Stroke is a leading cause of death and adult disability without treatment for long-term 
recovery. Stroke ranks number 5 as the leading cause of death in the United States and number 2 
worldwide.1 Among clinical stroke types, ischemic stroke accounts for 87% of all strokes and is 
caused by a clot in a cerebral blood vessel that leads to neural cell and tissue damage.2 There is a 
very limited window for stroke treatment. Current treatment methods all aim to return blood flow 
to the damaged tissue. One common treatment relies on the use of tissue plasminogen activator 
(tPA), which converts the enzyme plasminogen to plasmin to break down the clot. The second 
common treatment is endovascular thrombectomy, which is the physical removal of the clot using 
a stent retriever. Both treatments are widely used in stroke clinics; however, these procedures must 
be applied within 24 hours of stroke onset (tPA within 3-4.5 hours; thrombectomy within 24 
hours).3 Despite efforts to restore neural functions, there are no treatment currently available for 
long-term recovery from stroke.  
 Ischemic stroke results from cessation of blood flow and is characterized by a distinct area 
of necrotic tissue termed the infarct core. Surrounding the infarct core is a hypoperfused region 
known as the ischemic penumbra, where the tissue is damaged and at risk of complete cell death.4 
Blood flow to the penumbra continues to deliver oxygen and glucose to the surviving cells. 
However, this region is subject to a wave of deleterious inflammatory response and metabolic 
stress propagated from the core, leading to the expansion of ischemic injury and the subsequent 
worsening of clinical outcome within 24 hours to 7 days after stroke onset.4,5 This ischemic 
recruitment process establishes a time frame for reperfusion therapies to save the penumbral tissue, 
making this area a target for extending the therapeutic window, brain plasticity, and 
neuroprotective and neurorepair treatments.4,5 Deficits after stroke improve with time, suggesting 
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that the brain has at least some capacity for repair.6 In stroke patients, microvessel density in the 
penumbra tends to increase and this increase is correlated with longer survival. This 
neovascularization represents one mechanism that might mediate the repair process.7,8  
 In the adult brain, post-stroke neural repair involves a number of processes of anatomical 
and functional changes, including axonal sprouting, remapping of cortical networks, angiogenesis, 
and neurogenesis.8 Angiogenesis is defined as the growth and remodeling of the vasculature. 
Neurogenesis is the proliferation and differentiation of neural stem cells into neuronal and glial 
lineages.9 Post-stroke angiogenesis and neurogenesis have been demonstrated in rodents, primates 
and humans.6,10 In adult rodents and mammalians, neurogenesis occurs in the subventricular zone 
(SVZ) in the lateral region of the ventricles and the subgranular zone (SGZ) of the hippocampus. 
Stem cells in the SGZ differentiate and migrate to the dentate gyrus granule cell layer and is 
important for learning and memory.11,12 Neurogenesis in the SVZ gives rise to neuroblasts, which 
are immature neurons that migrate in chains along blood vessels to the olfactory bulb in a process 
known as the rostral migratory stream. Once neuroblasts reach the olfactory bulb, they detach and 
differentiate into periglomular and granule neurons, but only some survive long-term and integrate 
into the circuitry.13,14 The association between the neuroblasts and the blood vessels guiding them 
to the olfactory bulb are mediated by molecules that induce cell-to-cell interaction.15 These 
processes that normally occur in the adult brain indicate the brain has some capacity for repair and 
plasticity. 
In rodent models of stroke, focal ischemia potently stimulates SVZ cell proliferation and 
neurogenesis that gives rise to new neurons in the regions adjacent to the infarct cortex.11,16–20 A 
closer examination of these stroke-responsive neuroblasts reveals a close association with 
angiogenic vessels. Large clusters of neuroblasts localizes to newly born endothelial cells in the 
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peri-infarct, forming a regenerative neurovascular niche.19,21–23 These angiogenic vessels act as a 
scaffold that provide directional guidance for the neuroblasts to the peri-infarct region. Systemic 
administration of pro- and anti-angiogenic factors induce or inhibit the growth of new vessels, 
respectively, and neuroblast migration to the peri-infarct core is modulated accordingly. These 
stroke-responsive neuroblasts arise from the SVZ and is diverted away from their typical path to 
the olfactory bulb. This stimulation of long-distance migration of SVZ-derived neural progenitor 
cells to the stroke peri-infarct cortex suggests that post-stroke angiogenesis and neurogenesis are 
casually linked. Furthermore, in human stroke, there is evidence of stroke-induced neurogenesis 
with new born neurons residing in close proximity to the blood vessels in the ischemic penumbra.10 
These implications suggest stimulating post-stroke neurogenesis and angiogenesis to promote the 
proliferation and migration of neural progenitor cells may contribute to functional recovery. 
However, molecular mediators of the interaction between migrating neuroblasts and the 
remodeling vasculature in the peri-infarct niche are not known. 
A former graduate student in the Carmichael Laboratory previously established a 
microarray and bioinformatics dataset that described molecular pathways potentially involved in 
the bidirectional signaling between stroke-responsive neuroblasts and angiogenic blood vessels. 
The analysis consisted of gene expression profiles of migrating immature neurons derived from 
the SVZ and endothelial cells in the peri-infarct cortex. These gene systems code for secreted or 
membrane-bound products that can signal to endothelial cells to promote angiogenesis and 
migration of the neuroblasts. Three candidate gene sets were selected based on the amount and 
statistical significance of gene expression change and available literature that support a functional 
role in vascular or stem cell progenitor differentiation. This study aims to determine the functional 
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role of CCL9, Wnt7a, and PTN in post-stroke angiogenesis and neurogenesis, and whether their 
modulation of these processes contribute to functional recovery after stroke. 
CCL9 is a chemokine ligand produced in macrophages, osteoclasts, and functions as a cell 
survival factor. Chemokines are known to induce directed chemotaxis of responsive cells and can 
promote cell migration during brain development.24 Some chemokines are released as an 
inflammatory response to injury; however, several other chemokines, such as stromal cell-derived 
factor 1 (SDF-1a) are known to promote neuronal cell migration during normal and post-stroke 
angiogenesis in the peri-infarct zone.21,25 CCL9 is largely linked to tumor angiogenesis and cell 
growth.26 In vitro, the human homolog of CCL9, CCL15, increase endothelial cell proliferation 
and differentiation through the chemokine (C-C motif) receptor 1 (CCR1).27 Current literature has 
linked CCL9 to tumor angiogenesis and expansion, however, its role in CNS and neural repair is 
not clearly understood, making this a novel target for potential regenerative therapies. 
PTN is a heparin-binding cytokine normally expressed in mature neurons and has 
mitogenic activity that promotes brain capillary endothelial cell proliferation.28,29 Similar to CCL9, 
PTN is overexpressed in tumors and stimulates tumor angiogenesis and endothelial cell 
proliferation after myocardial infarctions.30,31 Additionally, PTN induces neurite outgrowth and 
vasculogenesis during development and has post-developmental neurotrophic and neuroprotective 
functions.28,32 After acute ischemic brain injury, the PTN gene is upregulated in microvasculature, 
macrophages, and astrocytes in the peri-infarct cortex.33 These evidences suggest PTN may be a 
key contributor to recovery of brain function after stroke.  
Wnt7a has been extensively studied in angiogenesis and neurogenesis in the developing 
and adult central nervous system (CNS). Wnt7a stimulates neural progenitor proliferation and 
differentiation in the embryonic and neonatal mouse brain and can regulate multiple steps of 
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neurogenesis through canonical signaling via activation of b-catenin. Loss of Wnt7a lead to 
reduced neural stem cell self-renewal and decreased neuronal maturation and differentiation, as 
well as defects in vascular formation and blood-brain barrier integrity.34,35 These pro-angiogenic 
and neurogenic properties of Wnt7a, CCL9, and PTN suggest these targets are potentially 
important in regulating neural repair processes in the neurovascular niche after stroke.  
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Materials and Methods 
Animal Treatment and Microsurgeries 
Microarray and Bioinformatics Analysis 
Focal cortical strokes were produced in 2-month-old male doublecortin promoter-red 
fluorescent protein (DCX-RFP) transgenic mice (gift of Dr. E. Masliah, UCSD) using a model of 
permanent distal middle cerebral artery and transient (15 minutes) bilateral common carotid 
artery occlusion. Brains were collected 7 days after stroke and thin sections were stained for 
platelet endothelial cell adhesion molecule (PECAM) to label both remodeling (angiogenic) and 
mature blood vessels. Angiogenic vessels were identified based on their location within peri-
infarct cortex (< 500um from the infarct core) and their larger, more disorganized morphology. 
PECAM+ endothelial cells from peri-infarct angiogenic blood vessels were isolated using a laser 
capture microdissection system (Molecular Devices). DCX-RFP+ neuroblasts adjacent to the 
angiogenic vessels were isolated using fluorescence-activated cell sorting. Isolated and amplified 
RNA were used to probe whole genome arrays (mouseRef-8, Illumina for neuroblasts, Agilent 
mouse arrays for vessels). Samples of 20 animals were used for gene expression study. 
Differential gene expression was assessed via contrast analysis using the LIMMA package. After 
linear model fitting, a Bayesian estimate of differential expression was calculated using a false 
discovery rate of 0.001%. Similar isolation and array analysis were performed with respective 
control cells: normal endothelial cells from cortex contralateral to the stroke, and normal 
neuroblasts that had migrated to the olfactory bulb. Bioinformatics analysis was completed at the 
Informatics Center for Neurogenetics and Neurogenomics (ICNN) at UCLA to determine which 
genes interact. 
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Gain- and loss-of-function studies 
Lentiviruses with a EF1a promoter driving the expression of a BFP or GFP reporter and 
Wnt7a, PTN, or CCL9 was injected into the left motor cortex of 2-month-old male C56BL/6J 
mice (Jackson Lab) 14 days before stroke [anterior/posterior (A/P): 0 mm, medial/lateral (M/L): 
-0.5mm, -2.5mm, dorsal/ventral (D/V): 0.75mm]. Rose Bengal dye [10mg/ml] was injected at a 
volume of 10µL/g intraperitoneally and allowed to diffuse and enter the blood stream for 5 
minutes. A fixed light source (180mV) is placed in the left motor cortex (M/L: -1.5mm; 18 
minutes). 2’-deoxy-5’-ethynyluridine (EdU; Carbosynth NE08701) is given in drinking water at 
200µg/ml starting 24 hours before stroke for 7 consecutive days after stroke. Body temperature 
was maintained at 37.0 °C with a heating pad throughout the procedure.  
  
Tissue Processing and Immunohistochemistry 
Brains were perfused with 2% paraformaldehyde using the periodate-lysine-
paraformaldehyde (PLP) perfusion followed by 24 hours of post-fixation as described.36 Tissues 
were cryosectioned into 40µm sections. Immunohistochemistry: Day 1: tissues were rinsed in 
0.02M potassium phosphate buffered saline (KPBS) and blocked for 45 minutes in 5% normal 
donkey serum (NDS) and 0.03% triton in 0.02M KPBS followed by overnight incubation in 
primary antibodies, 2% NDS, and 0.1% triton in 0.02M KPBS. Day 2: Tissues were incubated in 
a secondary antibody solution for 1 hour (Jackson ImmunoResearch) followed by a 10-minute 
wash in DAPI. EdU labeling: tissues were incubated for 30 minutes in EdU cocktail that 
consisted of 4mM copper sulfate, 100mM sodium ascorbate, 100mM tris-buffered saline pH 7.6, 
and 2µM sulfo-Cy5 azide (Lumiprobe, C3330). Primary antibodies: rat anti-CCL9 (Biorbyt 
A2444), rabbit anti-NeuN (Abcam, ab177487), guinea pig anti-DCX (Millipore EMD AB2253), 
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rabbit anti-Olig2 (Millipore EMD AB9610), rat-CD31 (BD Pharmingen, 553370), goat-PTN 
(Santa Cruz, sc-1394), mouse anti-Wnt7a (Santa Cruz, sc-365459), rat anti-GFAP (Life 
Technologies, 130300), goat anti-Iba1 (Abcam, ab5076) 
 
Behavior Assessment 
Mice (n = 12) were tested on grid-walking and cylinder tests. Baseline motor function 
was measured 1 day before virus injection followed by a photothrombotic stroke as described 
previously. Both tests were measured at 1, 4, and 8 weeks post-stroke. For the grid-walk test, 
animals were placed on a metal grid and were allowed to move freely for 5 minutes of recording 
time. For the cylinder test, animals were placed inside a clear plastic cylinder and were allowed 
to explore during the 5-minute recording time. 
 
Data Analysis and Statistics 
Imaris Image Analysis Software was used to quantify neuron, neuroblast, endothelial cell, 
vessel, and microglia densities. Cortical DCX+/DAPI+/EdU+, NeuN+/EdU+ and CD31+/EdU+ 
cell and vessel densities were tested with one-way ANOVA. Behavior data was analyzed using 
two-way ANOVA. Microglia density and glut-1 expression were analyzed using Student’s t-test. 
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Results 
Microarray Dataset Presents Differentially Expressed Genes in Neuroblasts after Stroke 
Doublecortin-promoter-red-fluorescence-protein (DCX-RFP) transgenic mice underwent 
a focal cortical stroke produced by a model of permanent distal middle cerebral artery and transient 
bilateral common carotid artery occlusion (MCAo) (Fig 1A). These mice were sacrificed at 7 days 
after stroke, a time of peak neurovascular association.21 Expression profiles of angiogenic 
endothelial cells from the peri-infarct zone was compared with non-angiogenic endothelial cells 
from the contralateral hemisphere. Regenerating neuroblasts adjacent to the angiogenic vessels in 
the peri-infarct cortex was compared with the normally migrating neuroblasts in the olfactory bulb. 
A comparison of whole genome expression profiles show a set of genes with significant changes 
in expression (Fig 1B). A bioinformatic analysis then identified the protein products of gene sets 
that might interact. From this neurovascular interactome, we identified three differentially 
expressed ligands in regenerating neuroblasts that signal to their receptors on angiogenic vessels 
(Fig 1B). These ligand-receptor pairs include CCL9/CCR1, Wnt7a/Frizzled 5, and PTN/receptor 
protein tyrosine phosphatase (RPTPBb/z). With the exception of CCL9, Wnt7a and PTN are both 
downregulated after stroke based on the microarray analysis (Table 1, CCL9: +3.040-fold change; 
Wnt7a: -0.591-fold change; PTN: -0.330-fold change). Expression of these genes in the brain were 
validated with immunohistochemistry. PTN is expressed in mature neurons in a naïve mouse (Fig 
2A). Immunostaining validation shows decreased Wnt7a expression in stroke-responsive 
neuroblasts compared to its normal expression in neuroblasts in the olfactory bulb at 7 days after 
stroke as well as normal expression in mature neurons in a non-stroke control animal (Fig 2C). 
CCL9 expression was found to be upregulated in the peri-infarct region after stroke (Fig 2B). These 
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data confirm the expression of our genes of interest in the brain and specifically in neuronal cell 
types. 
 
Neuroblast-Derived Factors Regulate Neurogenesis after Cortical Ischemic Stroke 
A mechanistic overexpression and knockdown approach was used to examine the 
functional role of CCL9, Wnt7a, and PTN in the neurovascular niche after stroke. To induce 
overexpression of these genes, a lentivirus expressing the EF1a promoter drove the expression of 
CCL9, Wnt7a, or PTN (Fig 3A). The virus was injected into the motor cortex of 2-month-old 
C57BL/6 male mice 14 days before stroke (Fig 3A). Downregulation of these genes was completed 
using a microRNA (miR) construct also expressed under the EF1a promoter (Fig. 3A). Respective 
control groups for the overexpression and knockdown studies will be termed expression control 
and miR control. Expression of virus after 14 days is indicated by a blue fluorescent reporter (BFP) 
and is found in both mature neurons and astrocytes, as shown by co-labeled BFP+/NeuN+ and 
BFP+/GFAP+ cells, respectively (Fig. 3B and C). To mark proliferating cells, we provided a 
thymidine analogue, EdU, in drinking water for 8 consecutive days starting 1 day before stroke.  
To elucidate the impact of these ligands on the ongoing cellular processes in the 
perilesional region after stroke, we used the photothrombosis (PT) stroke model to produce a 
localized ischemic cell death in the motor cortex. Similar to the MCAo model, this technique also 
leads to a hypoperfused region adjacent to the infarct core, mimicking the ischemic penumbra in 
human brain tissue after stroke (Fig 3A).37 The PT model induces the migration of neural 
progenitor cells from the SVZ in a similar fashion as MCAo. To confirm this, we utilized 
Ascl1(Mash1)-CreERT2::tdTomato transgenic mice and administered tamoxifen for 5 consecutive 
days after stroke. Co-labeling of neural progenitor cell marker DCX and tdTomato at 3 and 10 
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days after stroke showed gradual migration of SVZ-derived neural progenitor cells from the SVZ 
to the peri-infarct region (Fig 4A, B).  
Adult neurogenesis begins with neural stem cells that differentiate into neuroblasts at 1-2 
weeks marked by the expression of DCX, followed by maturation into neurons which express 
nuclear antigen NeuN at 4-8 weeks.38 To examine short term neurogenesis regulated by CCL9, 
Wnt7a, and PTN, we quantified the density of immature neuroblasts at 14 days after stroke. 
Regions used for quantification included the peri-infarct cortex, the white matter, as well as the 
SVZ to accurately evaluate the total number of migrating stroke-responsive neuroblasts (Fig. 5A). 
We used nuclear marker 4′,6-diamidino-2-phenylindole (DAPI) to localize single DCX+ cells. Co-
labeling of DCX, DAPI, and EdU showed increased neuroblast density in CCL9 overexpressing 
animals, however, this effect was not statistically significant compared to expression control 
animals (expression CCL9: 35.11 ± 13.81 vs expression control: 12.76 ± 2.80 cells per mm2; 
ANOVA: P> 0.05) (Fig. 5B and C). Wnt7a and PTN upregulation showed similar levels of 
increased in DCX+ DAPI+ EdU+ cells, but these increases are not significantly high (expression 
Wnt7a: 21.77 ± 6.81, expression PTN: 22.58 ± 3.63 cells per mm2; ANOVA: P> 0.05) (Fig. 5B 
and C). In microRNA knockdown conditions, Wnt7a and CCL9 downregulation both showed 
similar neuroblast densities compared to miR control group (miR Wnt7a: 15.40 ± 3.14, miR CCL9: 
12.45 ± 2.10 vs. miR control: 10.45 ± 2.19 cells per mm2; P>0.05) (Fig. 5B and C). Interestingly, 
this increase was significantly higher in the PTN knockdown group (28.56 ± 5.65 cells per mm2; 
ANOVA: P<0.01) (Fig. 5B and C). 
Long-term neurogenesis was assessed based on the density of mature neurons in the peri-
infarct cortex. CCL9 upregulation showed a significantly higher density of NeuN+/EdU+ mature 
neurons compared to expression control animals (expression CCL9: 8.48 ± 0.76 vs. expression 
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control: 1.67 ± 0.48 cells per mm2; ANOVA: P<0.0001) (Fig. 6A and C) Similarly, Wnt7a 
upregulation also showed an increase in mature neurons 42 days after stroke (expression Wnt7a: 
5.14 ± 0.89; ANOVA: P<0.01) (Fig. 6A and C). The PTN overexpression group, however, did not 
display an increase in neuronal cells long-term after stroke (expression PTN: 1.13 ±  0.60 cells per 
mm2; ANOVA: P>0.05). microRNA knockdown experiments showed CCL9 downregulation after 
stroke drastically decreased the number of mature neurons in the peri-infarct cortex (miR CCL9: 
3.40 ± 0.61 vs. miR control: 15.29 ± 4.87 cells per mm2; ANOVA: P<0.05) (Fig. 6A and B). This 
downregulation was also consistent with PTN knockdown (miR PTN: 3.56 ± 1.13 cells per mm2; 
ANOVA: P<0.05) (Fig. 6A and B). However, Wnt7a knockdown did not produce a significant 
decrease in NeuN+ EdU+ cells after stroke (miR Wnt7a: 6.52 ± 1.47 cells per mm2; ANOVA: 
P>0.05) (Fig. 6A and B). Interestingly, expression and microRNA control groups had different 
levels of NeuN+EdU+ cell densities, suggesting a potential off-target effect of the microRNA itself 
(expression control: 1.67 ± 0.48 vs. miR control: 15.29 ± 4.87 cells per mm2). These experiments 
show Wnt7a and CCL9 has a functional role in increasing neurogenesis after stroke by inducing 
migration of immature neural progenitor cells and promoting the differentiation of neuroblasts into 
mature neurons. 
 
Neuroblast-Secreted Factors Mediate Angiogenesis 
To examine whether functional overexpression or knockdown affect stroke-induced 
angiogenesis, we first examined endothelial cell proliferation, using the co-labeling of endothelial-
biomarker cluster of differentiation 31 (CD31), and EdU. We compared angiogenesis at both short-
term (14 days) and long-term (42 days) time points after stroke. 14 days after stroke, induced 
expression of CCL9 slightly increased the density of newly proliferated endothelial cells compared 
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to stroke expression control group, but this increase was not significant (expression CCL9: 702.60 
± 61.42 vs. expression control: 485.80 ± 65.06 cells per mm2; ANOVA: P >0.05) (Fig. 7A). PTN 
and Wnt7a upregulation both induced proliferation to a comparable level as stroke control 
expression group (expression PTN group: 599.20 ± 47.53 and expression Wnt7a group: 466.00 ± 
102.10 vs expression control group: 485.80 ± 65.06 cells per mm2; ANOVA: P>0.05) (Fig. 7A). 
Wnt7a downregulation drastically decreased the density of new endothelial cells compared to miR 
control animals (miR Wnt7a: 315.00 ± 66.75 vs. miR control: 701.20 ± 102.70 cells per mm2; 
ANOVA: P<0.01) (Fig. 7A). This significant decrease was also observed in CCL9 knockdown 
animals (miR CCL9: 469.20 ± 39.81 vs. miR control: 701.20 ± 102.70 cells per mm2; ANOVA: 
P<0.05) (Fig. 7A). Endothelial cell proliferation was not significant in PTN knockdown animals 
relative to miR control group (597.00 ± 44.09 vs. 701.20 ± 102.70 cells per mm2; ANOVA: P>0.05) 
(Fig. 7A). At 42 days after stroke, increases in endothelial cell proliferation was more apparent in 
Wnt7a overexpressing animals (expression Wnt7a: 578.00 ± 134.10 vs expression control: 161.50 
± 8.80 cells per mm2; ANOVA: P<0.01) (Fig. 7A and B). This increase was most significant in 
CCL9 overexpression cohort (expression CCL9: 1,013.00 ± 53.92 vs expression control: 161.50 ± 
8.80 cells per mm2; ANOVA: P<0.0001) (Fig. 7A and B). PTN overexpression only showed slight 
increase in endothelial cell proliferation at 42 days after stroke, similar to the short-term effect 
(368.20 ± 43.03 cells per mm2; ANOVA: P>0.05) (Fig. 7A and B).  
In microRNA knockdown groups, Wnt7a downregulation did not decrease the number of 
CD31+EdU+ endothelial cells significantly relative to miR control animals (miR Wnt7a: 792.80 
± 86.22 vs miR control: 589.00 ± 76.48 cells per mm2; ANOVA: P>0.05) (Fig. 7A and B). This is 
potentially due to the stroke induced downregulation of Wnt7a in neuroblasts, as seen in the 
microarray analysis (Table 1). CCL9 knockdown, however, drastically decreased the density of 
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endothelial cells in the peri-infarct cortex (miR CCL9: 166.00 ± 22.62 vs. miR control: 589.00 ± 
76.48 cells per mm2; ANOVA: P<0.01) (Fig. 7A and B). Interestingly, PTN knockdown 
significantly increased the number of endothelial cells proliferated after stroke in the peri-infarct 
cortex and this increase was higher than the overexpression of PTN (miR PTN: 937.00 ± 89.81 vs. 
miR control: 589.00 ± 76.48 cells per mm2; ANOVA: P<0.01) (Fig. 7A and B).  
Angiogenesis was also evaluated using vessel density based on volume of CD31 expression. 
Similar to endothelial cell proliferation, Wnt7a, CCL9, and PTN overexpression did not produce 
significant increases in vessel density in the peri-infarct cortex 14 days after stroke (expression 
Wnt7a: 482,000 ± 129,727, expression CCL9: 495,800 ± 27,29, and expression PTN: 452,400 ± 
46,700 vs. expression Control: 247,600 ± 39,829 um3 per section; ANOVA: P>0.05) (Fig. 7A). 
However, Wnt7a knockdown significantly decreased vessel density compared to miR control 
animals, consistent with the decrease in endothelial cell proliferation at 14 days (miR Wnt7a: 
344,000 ± 65,648 vs. miR control: 496,600 ± 37,519 um3 per section; ANOVA: P<0.05) (Fig. 7A). 
CCL9 and PTN downregulation did not produce such changes relative to the miR control group 
(miR CCL9: 383,200 ± 29,047, miR PTN: 513,000 ± 8,972 vs. miR control: 496,600 ± 37,519 um3 
per section; ANOVA: P>0.05) (Fig. 7A). Quantification of vessel density at 42 days after stroke 
showed significant increases in Wnt7a overexpressing animals (expression Wnt7a: 436,590 ± 
93,766 vs. expression control: 199,539 ± 33,533 um3 per section; ANOVA: P<0.05) (Fig. 7A and 
B). This increase was induced by 3-fold in animals overexpressing CCL9 (expression CCL9: 
519,826 ± 38,434 vs. expression control: 199,539 ± 33,533 um3 per section; ANOVA: P<0.01) 
(Fig. 7A and B). Knockdown of CCL9, contrarily, decreased vessel density, consistent with the 
significant decrease endothelial cell density observed at 42 days post-stroke (miR CCL9: 135,195 
± 15,203 vs. miR control: 419,054 ± 42,298 um3 per section; ANOVA: P<0.01) (Fig. 7A and B). 
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Wnt7a knockdown did not impact vessel density compared to miR control animals (522,400 ± 
21,846 vs. 419,054 ± 42,298 um3 per section; ANOVA: P>0.05) (Fig. 7A and B). Among all 
treatment groups, animals injected with PTN overexpression virus showed a decrease in vessel 
volume and endothelial cell proliferation from 14 to 42 days after stroke. At 14 days, vessel density 
in animals overexpressing PTN was similar to animals with PTN knockdown and these levels in 
both cohorts did not differ significantly to their relative control animals (Fig 7A). However, at 42 
days after stroke, the PTN knockdown group had significantly higher vessel density compared to 
controls (miR PTN: 661,029 ± 95,813 vs. miR control: 419,054 ± 42,298 um3 per section; ANOVA: 
P>0.05) (Fig. 7A and B). Furthermore, this increase in vessel density was higher than in the PTN 
overexpression group (expression PTN: 165,982 ± 14,905 vs. miR PTN: 661,029 ± 95,813 um3 
per section) (Fig 7A). This trend in induced vessel density in PTN knockdown group at the long-
term timepoint was similar to endothelial cell proliferation.  
Interestingly, expression and miR control groups showed inconsistent results in both 
endothelial cell proliferation and vessel density, with the miR control group showing consistently 
higher values in both short- and long-term time points (endothelial cell proliferation: 14d: 485.80 
± 65.06 vs. 701.20 ± 102.70 cells per mm2, 42d: 161.50 ± 8.80 vs. 589.0 ± 76.48 cells per mm2; 
vessel density: 14d: 247,600 ± 39,829 um3 per section vs. 496,600 ± 37,519 um3 per section, 42d: 
199,539 ± 33,533 vs. 419,054 ± 42,298 um3 per section) (Fig 7A). These gain- and loss-of-function 
data suggest Wnt7a and CCL9 may have larger functional roles than PTN. Regulation of these two 
genes can significantly impact angiogenesis and neurogenesis after stroke and may potentially 
mediate neural repair.  
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Wnt7a gain-of-function after stroke supports blood-brain-barrier formation  
CNS angiogenesis and blood-brain-barrier (BBB) formation are tightly coupled in 
development.39 Endothelial cells are an important member in the neurovascular unit and have a 
key role in BBB function by regulating the movement of ions, molecules, and cells between the 
blood and the brain.40 Wnt7a plays an important functional role in BBB formation and CNS 
angiogenesis during development.34 CNS endothelial cells form the BBB are characterized by 
the formation of tight junctions and the expression of transporters to selectively transport 
nutrients across the BBB.39 Wnt7a upregulation after stroke increased angiogenesis both at the 
short term and long term points (Fig. 7A and B). To determine whether this angiogenesis is 
linked to BBB formation, we examined the expression of the BBB endothelial cell-specific 
glucose transporter glut-1 in the peri-infarct cortex.41 We found that lentiviral-mediated 
overexpression of Wnt7a at 42 days after stroke increased the percentage of glut-1 expression by 
2-fold compared to expression control group (expression Wnt7a: 53.34 ± 4.135% vs. expression 
control: 24.32 ± 4.730% per section; Student’s t-test: P<0.01) (Fig 8A and B). This data supports 
previous findings that Wnt7a is functionally important for BBB formation and shows that, in 
addition to promoting CNS angiogenesis and neurogenesis, Wnt7a also improves BBB integrity 
long-term after stroke.  
 
CCL9-Mediated Microglia Proliferation 
CCL9 is a signaling chemokine ligand that bind to CCR1 receptors found on perivascular 
macrophages and microglial cells, the resident CNS parenchymal immune cells.42 To examine 
microglia proliferation in CCL9-treated groups, we co-labeled microglia/macrophage-specific 
biomarker ionized calcium binding adaptor molecule 1 (Iba1) and EdU+ to quantify microglial 
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density after stroke. Surprisingly, CCL9 overexpression did not significantly induce microglia 
proliferation (expression CCL9: 420.60 ± 22.87 vs. expression control: 363.50 ± 37.89 cells per 
mm2; Student’s t-test, P>0.05) (Fig. 9A and B). However, CCL9 knockdown significantly 
increased the number of microglia in the peri-infarct cortex at 42 days after stroke (miR CCL9: 
418.00 ± 47.39 vs. miR control 242.40 ± 48.82, cells per mm2; Student’s t-test, P<0.05) (Fig. 9A 
and B).   
 
Behavioral Assessment of CCL9 as a Novel Therapeutic Ligand 
An examination of angiogenesis and neurogenesis showed CCL9 modulates both processes 
after stroke. Currently, there has been little literature relating to a functional role of CCL9 in the 
brain and, especially, in neural repair. Thus, we set forth to determine whether altering the 
expression of CCL9 would mediate motor recovery of the injured limb. Gain- and loss-of-function 
lentivirus driving either the CCL9 or its microRNA-knockdown gene were injected into 2-month-
old mice 14 days before photothrombotic stroke. Two behavior tests were used to examine motor 
improvements after stroke: grid-walk and cylinder test. Animals were examined at 1, 4, and 8 
weeks post-stroke and were compared to baseline assessed 1 day before virus injection (Fig 10A). 
In the grid-walk test, all groups demonstrated deficit at 1 week after stroke (Fig 10B). CCL9 
overexpression group showed improvement at 4 weeks after stroke compared to stroke only group 
based on decreased in foot faults (expression CCL9: 0.058 ± 0.011 vs. stroke-only control: 0.184 
± 0.031 ratio of foot fault over total steps; ANOVA: P<0.0001) (Fig 10B). This improvement 
persisted to 8 weeks after stroke (expression CCL9: 0.065 ± 0.009 vs. stroke-only control: 0.123 
± 0.016 ratio foot fault over total steps; ANOVA: P<0.05) (Fig 10B). However, despite this 
significant improvement, CCL9 overexpression animals exhibited no significant differences in 
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improvement compared to expression control, miR control, and CCL9 knockdown groups. In the 
cylinder test, we examined motor improvement based on preference use the injured limb to touch 
the cylinder wall. Each assessment was normalized to baseline. In this task, we found no significant 
improvement in CCL9 overexpression animals compared to stroke-only control group. All 
experimental groups experienced deficits that persisted until 8 weeks after stroke. The stroke-only 
control group showed significant deficit in the injured limb at both 4 weeks and 8 weeks, but not 
1 week, after stroke (1 week: -0.459 ± 0.164, P>0.05, 4 weeks: -0.645 ± 0.132, P<0.01, 8 weeks: 
-0.601 ± 0.140; P<0.05) (Fig 10B). CCL9 can significantly modulate neurogenesis and 
angiogenesis after stroke. However, these behavior tests suggest those cellular changes mediated 
by CCL9 may not be sufficient for improvement from deficits. 
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Discussion 
 Stroke induces neurogenesis and angiogenesis in the tissue adjacent to the ischemic core, 
forming a unique neurovascular niche with capacity for regeneration.21 After cortical ischemic 
injury, SVZ-derived neuroblasts migrate along angiogenic blood vessels and differentiate in the 
regions adjacent to the infarct.21,43,44 However, the specific signals involved in this stroke-induced 
neuroblast-vascular association is largely unknown. Using microarray and bioinformatic analysis, 
we identified a list of differentially regulated ligand-receptor pairs derived from neuroblasts and 
endothelial cells in the neurovascular niche. From this list, we investigated the functional 
properties of three of these ligands in mediating neurogenesis and angiogenesis. These ligands 
were CCL9, Wnt7a, and PTN.  
A set of gain- and loss-of-function studies using lentiviral-mediated overexpression and 
knock-down demonstrated these signaling ligands can induce neurogenesis and angiogenesis in 
the short-term and, more significantly, in the long-term recovery time points after stroke. Gain of 
Wnt7a function after ischemia increased the density of mature neurons, endothelial cells, and 
overall vessel volume in the long-term but not short-term period after stroke. Wnt7a expression is 
vital for CNS vascular formation during development; Wnt7a inhibition leads to CNS-specific 
vessel defects.34 The pro-angiogenic property of Wnt7a found in this study supports its relevance 
in CNS angiogenesis, and more importantly its functional role in promoting angiogenesis after 
ischemic injury in an adult mouse model. Further, we demonstrated Wnt7a increase the expression 
of a BBB endothelial cell-specific glucose transporter, indicating the possibility that in addition to 
promoting angiogenesis it also drives barrier formation in the newly formed vessels. This is 
particularly important as the movement of toxins and nutrients between the blood and the brain 
are tightly controlled by the expression of specific transporters in the BBB.40,45 As ischemia 
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progresses, the BBB becomes increasingly permeable, leaving brain tissue vulnerable to a plethora 
of inflammatory responses and toxins that further aggravate injury.46,47 Formation of the BBB in 
angiogenic vessels would facilitate the influx and efflux of nutrients and maintain CNS 
homeostasis and proper functions of remaining and newly differentiated neurons. Gain-of Wnt7a 
function increased neurogenesis in the long-term period after stroke. This result aligns with 
previous studies which have demonstrated the neurogenic property of Wnt7a in the naïve mouse 
brain. Extensive studies have shown Wnt7a stimulates proliferation and differentiation of 
embryonic and neonatal neural progenitor cells derived from mouse brains.48,49 In the adult mouse, 
Wnt7a regulates multiple steps of neurogenesis and promotes cell renewal and cycle 
progression.35,50 The Wnt7a/canonical signaling pathway is critical in these angiogenic and 
neurogenic changes. This pathway begins with the activation of the Frizzled receptor followed by 
stabilization of b-catenin, activating downstream targets.51 Blockade of b-catenin leads to vascular 
malformation and loss of BBB-specific transporters during development.34 b-catenin signaling 
also promotes neural stem cell self-renewal, neural progenitor cell progression and differentiation, 
and synaptic input in the adult SVZ and hippocampus.35,50 Based on these findings, Wnt7a-induced 
angiogenesis and neurogenesis after-stroke may be regulated by canonical signaling through b-
catenin and its downstream effectors. Targeting the molecules downstream of this pathway may 
be crucial to the neurovascular regenerative process. Specifically, Cyclin D1, a downstream target 
of b-catenin, regulates early steps of neurogenesis by promoting neural progenitor proliferation; 
and, in later stages of neurogenesis, activation of neurogenin 2 leads to neuronal differentiation 
and maturation.35,52 Furthermore, Wnt7a promotes hippocampal synapse formation and axonal 
guidance during critical developmental stages; both of these processes are important for the 
function and integration of new neurons and can lead to functional recovery.53–58 Future 
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experiments could focus on determining whether Wnt7a expression alters synaptogenesis and 
axonal remodeling of existing and newly differentiated neurons after stroke after stroke to better 
characterize the functionality of these neurons in the neurovascular niche. Further, b-catenin and 
its downstream targets such as Cyclin D1 and neurogenin after stroke should be examined to see 
whether activating the signaling pathway directly can further increase the angiogenic and 
neurogenic response after stroke and whether this can increase synaptic formation and integration 
of newly differentiated neurons into cortical network. 
PTN is a heparin-binding protein that stimulates mitogenesis, angiogenesis, and neurite 
and glial process guidance during embryogenesis and early development.33 The PTN gene is 
predominantly expressed in cortical neurons in adult mouse brains.59 After acute ischemia, up-
regulation of PTN have been discovered in astrocytes, macrophages, and endothelial cells.33 
Adding to that discovery, our microarray data showed increased PTN expression in SVZ-derived 
neuroblasts in the peri-infarct cortex. This is consistent with previous findings which have found 
increased PTN expression after injury and during repair in the brain.28 Other findings have shown 
PTN secretion increases tumor angiogenesis and the formation of new blood vessels after cerebral 
ischemia.60,61 In this study, PTN overexpression increased endothelial cell proliferation and vessel 
density increased slightly at 14 days but returned to baseline at 42 days after stroke. Interestingly, 
PTN knockdown significantly increased both endothelial cell and vessel densities at 42 days after 
stroke. This result conflicts with previous findings which showed PTN secretion stimulates 
endothelial cell proliferation and angiogenesis in human glioma.29,60 Similar to angiogenesis, PTN 
overexpression resulted in similar densities of neuroblasts and mature neurons compared control 
animals at 14 and 42 days after stroke. However, PTN knockdown induced a greater number of 
neuroblast proliferation, but the number of mature neurons drastically decreased to baseline at 42 
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days. These data suggest that PTN expression after stroke may potentially inhibit neuronal 
proliferation, but this inhibition is released with PTN knockdown and other secreted factors may 
be necessary to regulate later steps of neurogenesis to promote differentiation into mature neurons. 
This implies that PTN may have an inhibitory role in later stages of post-stroke neurogenesis. 
Since stroke-induced neuroblast migration is linked to angiogenesis in the peri-infarct cortex, the 
significant increase in long-term angiogenesis with PTN knockdown is perhaps due to growth 
factors and other signaling ligands secreted by the increase in neuroblast density found in the acute 
period after stroke.43 PTN signals through a transmembrane receptor protein tyrosine phosphatase, 
RPTPb/z, whose activity is inactivated upon PTN binding, leading to persistent phosphorylation 
of a variety of substrates.60 One of these substrates is b-catenin, a downstream protein also 
activated by Wnt7a.62 Future experiments could combine PTN knockdown and Wnt7a up-
regulation based on the results of this study and examine whether Wnt7a upregulation can increase 
the differentiation of neuroblasts that are initially induced by PTN knockdown. 
 CCL9 up-regulation in the peri-infarct cortex after stroke increased both neurogenesis and 
angiogenesis long-term. CCL9 expression increased neuroblast proliferation and differentiation 
into neurons and endothelial cell proliferation and vascular density. However, this significance 
was only observed at 42 days after stroke, suggesting this regenerative effect may take longer than 
the 14-day period. CCL9 down-regulation, contrarily, decreased these effects. These data in tissue 
repair suggested CCL9 might serve as a therapeutic target for functional recovery. However, 
behavioral assessment of motor movements in mice with CCL9 up-regulation did not show 
consistent improvement across the grid-walk and cylinder tests. CCL9 overexpression animals 
showed improvements at 4 and 8 weeks after stroke compared to stroke-only control animals in 
the grid-walk test; but this improvement was not significantly different compared to expression 
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virus control, CCL9 microRNA knockdown, or microRNA knockdown virus control animals. 
Furthermore, there was no significant improvements in CCL9 overexpressing animals relative to 
stroke-only animals in the cylinder task. Together, these data show CCL9 has a regenerative effect 
on neural repair, but these effects are not sufficient to generate functional recovery. CCL9, 
normally expressed in macrophages, signals through CCR1 and induces tumor angiogenesis 
through myeloid progenitor cell recruitment.24,26,63 Microglia cells are the resident immune cells 
in the brain.64 Upon examination of microglia density after stroke, there was no apparent increase 
in CCL9 overexpression groups compared to control animals. Interestingly, CCL9 knockdown 
produced moderated increase compared to microRNA knockdown control animals. However, the 
densities between CCL9 overexpression and knockdown were similar, suggesting CCL9 does not 
significantly affect microglia recruitment after stroke. This is contrary to findings that show CCL9 
induces tumor angiogenesis through macrophage recruitment.65 One possible explanation for the 
angiogenic effect in our studies is that CCL9-induced angiogenesis in the stroke is not mediated 
through microglia. CCL9 can potentially target the CCR1 receptor on the endothelial cells directly 
to stimulate proliferation and vessel growth. Additionally, inflammatory response following 
ischemia induces the release of a variety of chemokines and cytokines that activates microglia and 
recruit peripheral infiltrating macrophages.66 Therefore, mediating CCL9 expression alone may 
not be sufficient to drastically alter microglial activation, while other chemokines may play a larger 
role in the inflammatory response. CCL3, a macrophage inflammatory protein that also signals 
through CCR1, is also induced in focal cerebral ischemia; its induction exacerbates injury that is 
correlated to the recruitment of inflammatory immune cells.67,68 Other studies have shown human 
colon cancer cells secrete CCL9 and blocking CCR1 decreased myeloid cell accumulation.69 Based 
on these findings, blockade of the CCR1 receptor after stroke may be a better target to examine 
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and enhance motor recovery and microglial proliferation. Using CCR1 antagonists can potentially 
have an enhanced effect on tissue repair and functional recovery, especially given that CCL9 
expression did not change behavioral outcomes.  
In this study, we discovered a set of gene products isolated from the neurovascular niche 
and defined the functional effect of a small set of those genes on both tissue regeneration and 
behavioral recovery. The workflow developed in this study demonstrated stroke-responsive 
neuroblast-derived ligands, Wnt7a, CCL9, and PTN, can mediate post-stroke neurogenesis and 
angiogenesis. One limitation of  this selection approach is that gene products were chosen based 
on results from microarray analysis, which needs to be further validated and does not precisely 
describe post-translational modifications that can regulate the activity of signaling ligands and 
their interaction with receptors.70,71 A more rigorous validation of the microarray data using in situ 
hybridization chain reaction can demonstrate the precise location within the neuroblast of these 
signaling molecules and their respective receptors on the endothelial cells. Nevertheless, we have 
established a set of gene products that are at least partially involved in the interaction between 
neuroblasts and angiogenic vessels in the stroke neurovascular niche. Further explorations of this 
dataset can lead to a better understanding of the precise mechanisms involved in this cellular 
interaction and can potentially lead to promising therapeutic targets for clinical recovery. 
 
 
 
 
 
 
  
 25 
Figure 1. Microarray and bioinformatics analysis of cellular interactions in the peri-infarct 
cortex. (A) Confocal micrograph of DCX+ neuroblasts migrating to the infarct in MCAo stroke 
tissue. (B) Schematic of the regenerating Neurovascular Interactome. Stroke-responsive 
neuroblasts and endothelial cells from the peri-infarct and contralateral cortex and olfactory bulb 
are isolated 7 days after a MCAo stroke. (Scale Bar: 1000µm). 
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Figure 2. Ligand expression in naïve and stroke animals. (A) Confocal micrograph of PTN 
expression in NeuN+ cells in the cortex of a 2-month-old naïve animal. (Scale bar: 50µm). (B) 
CCL9 expression adjacent to CD31+ vessels in the peri-infarct cortex 7 days after stroke. (Scale 
bar: 50µm). (C) Confocal micrograph of Wnt7a expression found in NeuN+ cells in the cortex and 
DCX+ cells in the olfactory bulb of a naïve animal, but not in DCX+ cells in the SVZ 7 days after 
stroke. (Scale bar: 50µm).  
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 27 
C. 
 
  
 28 
Figure 3. Gain- and loss-of-function virus expression after stroke. (A) Low magnification 
confocal micrograph of viral expression in whole brain coronal section 14 days after 
photothrombotic stroke. Lentiviruses are injected into the medial and lateral cortex of the animal 
14 days before stroke. (Scale bar: 1,000µm). (B) Confocal micrograph of lentiviral expression 
indicated by BFP+ cells in the motor cortex 14 days after injection. (Scale bar: 100µm). (C) 
Confocal micrographs of transduced cells in the per-infarct cortex 14 days after injection. 
Arrowheads: BFP+ NeuN+ and BFP+ GFAP+ cells (Scale bar: 50µm). 
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Figure 4. Post-stroke neurogenesis in Ascl1-CreERT2::tdTomato transgenic line. (A, B) 
Expression of Ascl1-CreERT2::tdTomato cells at 3 days and 10 days after stroke. Tamoxifen was 
administered once per day from for 5 days after stroke. Confocal micrographs of migration of 
DCX+ tdTomato+ cells in the ipsilateral cortex at 3 days (A) and 10 days (B) after stroke. (Scale 
bar: 100µm) 
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Figure 5. Short-term post-stroke neurogenesis. (A) Low magnification confocal micrograph of 
a coronal section of a photothrombotic stroked brain. Expression of DCX+ cells in the 
subventricular zone (SVZ), white matter (WM), and the peri-infarct is shown in higher 
magnification. (Scale bar: 1,000µm in lower magnification, 100µm in higher magnification). (B) 
Quantification of DCX+ DAPI+ EdU+ neuroblast density 14 days after stroke. For all group 
comparisons, One-Way ANOVA, n= 5 for all groups, ** P<0.01. (C) Confocal micrographs of 
gain-of-function and loss-of-function CCL9, Wnt7a, and PTN treated animals. Arrowheads: Co-
labeled DCX+ DAPI+ EdU+ indicate stroke-induced neuroblast proliferation. (Scale bar: 30µm). 
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Figure 6. Long-term post-stroke neurogenesis. (A) Quantification of NeuN+ EdU+ cell density 
42 days after stroke. (B) Confocal micrographs of mature neurons in the peri-infarct cortex in gain- 
and loss-of-function groups. Arrowheads: NeuN+ EdU+ cells. One-way ANOVA, n=5 for all 
groups, * P<0.05, ** P<0.01, **** P<0.0001. (Scale bar: 12.5µm).  
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Figure 7. Post-Stroke angiogenesis. (A) Quantification of CD31+ EdU+ endothelial cells and 
CD31+ vessel density at 14 and 42 days after stroke. For all group comparisons, One-Way 
ANOVA, n=5 for all groups, * P<0.05, ** P<0.01, **** P<0.0001. (B) Confocal micrographs of 
angiogenesis at 42 days after stroke. Arrowheads: co-labeled CD31+ EdU+ endothelial cells. (Bar: 
50µm). 
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Figure 8. Wnt7a increases blood-brain-barrier formation. (A) Quantification of Glut1 
expression in Wnt7a overexpression and expression control animals 42 days after stroke. 
Student’s t-test, n=5 for all groups, **P<0.01. (B)  Confocal micrograph of Glut-1 expression in 
Wnt7a gain-of-function and control mice. (Bar: 50µm). 
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Figure 9. CCL9-Induced Microglial Activation. (A) Quantification of Iba1+ EdU+ cell density 
in the peri-infarct cortex 42 days after stroke. Student’s t-test, n= 5 for all groups, *P<0.05. (B) 
Confocal micrographs of Iba1+ EdU+ microglia assessed in the peri-infarct cortex 42 days after 
stroke. (Scale bar: 50µm). 
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Figure 10. Behavior assessment of CCL9 gain- and loss-of-function. (A) Gain-of-function and 
loss-of-function viruses were injected 2 weeks before stroke. Grid walk and cylinder tasks were 
assessed 1 day before virus injection to establish baseline and at 1 week, 4 weeks, and 8 weeks 
after stroke. (B) Quantification of foot faults in grid-walk test. Two-way ANOVA, *P<0.05, 
****P<0.0001. (C) Assessment of preference for injured over uninjured limb use. Two-way 
ANOVA, *P<0.05, **P<0.01, stroke-only vs. naïve animals, n=10 for all groups. 
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Table 1. Stroke-responsive neuroblast-derived ligands. 
 
Ligand Receptor Ligand 
Expression 
Fold Change 
Location Type 
CCL9 CCR1   3.040 Extracelluar 
Space 
Chemokine 
Wnt7a Frizzled 2/7   0.591 Extracelluar 
Space 
Growth 
factor 
PTN RPTPβ/ζ   0.330 Extracellular 
Space 
Growth 
factor 
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